S
Sergey Gorlatov
Researcher at National Institutes of Health
Publications - 43
Citations - 3510
Sergey Gorlatov is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Monoclonal antibody & Antibody. The author has an hindex of 21, co-authored 42 publications receiving 3101 citations.
Papers
More filters
Patent
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
TL;DR: In this article, a variant Fc region comprising at least one amino acid modification relative to a wild-type Fc regions was proposed, which was used for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function mediated by FcγR is desired.
Journal ArticleDOI
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors
Jeffrey B. Stavenhagen,Sergey Gorlatov,Nadine Tuaillon,Christopher Rankin,Hua Li,Stephen P. Burke,Ling Huang,Syd Johnson,Ezio Bonvini,Scott Koenig +9 more
TL;DR: In a xenograft murine model of B-cell malignancy, the greatest enhancement of an Fc-optimized anti-human B- cell mAb was accounted for by improved binding to FcgammaRIV, a unique mouse activating FcGammaR that is expressed by monocytes and macrophages but not natural killer cells.
Journal ArticleDOI
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
Paul A. Moore,Wenjun Zhang,G. Jonah Rainey,Steve Burke,Hua Li,Ling Huang,Sergey Gorlatov,Maria Concetta Veri,Sudeepta Aggarwal,Yinhua Yang,Kalpana Shah,Linda Jin,Sunan Zhang,Leilei He,Tengfei Zhang,Valentina Ciccarone,Scott Koenig,Ezio Bonvini,Syd Johnson +18 more
TL;DR: The ability of the CD19xTCR DART to inhibit B- cell lymphoma in NOD/SCID mice when coadministered with human PBMCs supports further evaluation of DART molecules for the treatment of B-cell malignancies.
Journal ArticleDOI
Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus
Pankaj Pal,Kimberly A. Dowd,James D. Brien,Melissa A. Edeling,Sergey Gorlatov,Syd Johnson,Iris Lee,Wataru Akahata,Gary J. Nabel,Mareike K. S. Richter,Jolanda M. Smit,Daved H. Fremont,Theodore C. Pierson,Mark T. Heise,Michael S. Diamond +14 more
TL;DR: Administration of a single dose of a combination of two neutralizing MAbs limited the development of resistance and protected immunocompromised mice against disease when given 24 to 36 hours before CHIKV-induced death.
Journal ArticleDOI
Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity
Deryk T. Loo,Ralph Alderson,Francine Chen,Ling Huang,Wenjun Zhang,Sergey Gorlatov,Steve Burke,Valentina Ciccarone,Hua Li,Yinhua Yang,Tom Son,Y Chen,Ann Easton,Jonathan C. Li,Jill Rillema,Monica Licea,Claudia B. Fieger,Tony W. Liang,Jennie P. Mather,Scott Koenig,Stanford J. Stewart,Syd Johnson,Ezio Bonvini,Paul A. Moore +23 more
TL;DR: Evaluation of MGA271 clinical utility in B7-H3–expressing cancer is supported, while validating a combination of a nontarget biased approach of intact cell immunizations and immunohistochemistry to identify novel cancer antigens with Fc-based mAb engineering to enable potent antitumor activity.